REGN4461

DRUG3 trials

Sponsors

Regeneron Pharmaceuticals

Conditions

Familial Partial LipodystrophyGeneralized Lipodystrophy (GLD)Healthy VolunteersLipodystrophyMetabolic AbnormalitiesMonogenic Obesity (MOB)

Phase 1

A Study to Examine the Safety, Tolerability and Biological Effects of REGN4461 in Healthy Volunteers

CompletedNCT03530514

Regeneron PharmaceuticalsHealthy Volunteers

Start: 2018-04-24End: 2020-01-27Updated: 2020-03-09

Phase 2

A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD)

TerminatedNCT05088460

Regeneron PharmaceuticalsFamilial Partial Lipodystrophy, Metabolic Abnormalities

Start: 2022-02-28End: 2024-04-18Updated: 2025-10-16

Unknown Phase

Expanded Access to REGN4461 for Patients With Diseases Associated With Deficient Leptin Signaling

Regeneron PharmaceuticalsGeneralized Lipodystrophy (GLD), Lipodystrophy, Monogenic Obesity (MOB)

Updated: 2026-03-12

Related Papers

Pharmacokinetics and pharmacodynamics of mibavademab (a leptin receptor agonist): Results from a first‐in‐human phase I study

Clinical and Translational Science2024-04-018 citations